Logo image of MNMD

MIND MEDICINE MINDMED INC (MNMD) Stock Fundamental Analysis

NASDAQ:MNMD - Nasdaq - CA60255C8850 - Common Stock - Currency: USD

7.63  -0.55 (-6.72%)

After market: 7.6979 +0.07 (+0.89%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MNMD. MNMD was compared to 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of MNMD have multiple concerns. MNMD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MNMD has reported negative net income.
MNMD had a negative operating cash flow in the past year.
In the past 5 years MNMD always reported negative net income.
MNMD had a negative operating cash flow in each of the past 5 years.
MNMD Yearly Net Income VS EBIT VS OCF VS FCFMNMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -30.59%, MNMD is in line with its industry, outperforming 52.97% of the companies in the same industry.
MNMD's Return On Equity of -37.30% is fine compared to the rest of the industry. MNMD outperforms 61.62% of its industry peers.
Industry RankSector Rank
ROA -30.59%
ROE -37.3%
ROIC N/A
ROA(3y)-55.67%
ROA(5y)-49.46%
ROE(3y)-73.83%
ROE(5y)-61.54%
ROIC(3y)N/A
ROIC(5y)N/A
MNMD Yearly ROA, ROE, ROICMNMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MNMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNMD Yearly Profit, Operating, Gross MarginsMNMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for MNMD has been increased compared to 1 year ago.
The number of shares outstanding for MNMD has been increased compared to 5 years ago.
MNMD has a worse debt/assets ratio than last year.
MNMD Yearly Shares OutstandingMNMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
MNMD Yearly Total Debt VS Total AssetsMNMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

A Debt/Equity ratio of 0.09 indicates that MNMD is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.09, MNMD is in line with its industry, outperforming 47.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
MNMD Yearly LT Debt VS Equity VS FCFMNMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 9.00 indicates that MNMD has no problem at all paying its short term obligations.
MNMD has a Current ratio of 9.00. This is in the better half of the industry: MNMD outperforms 80.00% of its industry peers.
A Quick Ratio of 9.00 indicates that MNMD has no problem at all paying its short term obligations.
MNMD's Quick ratio of 9.00 is fine compared to the rest of the industry. MNMD outperforms 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 9
Quick Ratio 9
MNMD Yearly Current Assets VS Current LiabilitesMNMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

More info and screens

1

3. Growth

3.1 Past

MNMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.58%.
EPS 1Y (TTM)-19.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MNMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.87% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.3%
EPS Next 2Y16.11%
EPS Next 3Y10.16%
EPS Next 5Y16.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNMD Yearly Revenue VS EstimatesMNMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
MNMD Yearly EPS VS EstimatesMNMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MNMD. In the last year negative earnings were reported.
Also next year MNMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNMD Price Earnings VS Forward Price EarningsMNMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNMD Per share dataMNMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.11%
EPS Next 3Y10.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MNMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIND MEDICINE MINDMED INC

NASDAQ:MNMD (2/21/2025, 8:00:01 PM)

After market: 7.6979 +0.07 (+0.89%)

7.63

-0.55 (-6.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-06 2025-03-06/amc
Inst Owners56.78%
Inst Owner Change-15.32%
Ins Owners0.84%
Ins Owner Change-1.39%
Market Cap559.51M
Analysts85
Price Target26.41 (246.13%)
Short Float %14.12%
Short Ratio5.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.98%
Min EPS beat(2)5.46%
Max EPS beat(2)22.5%
EPS beat(4)2
Avg EPS beat(4)-27.11%
Min EPS beat(4)-111.45%
Max EPS beat(4)22.5%
EPS beat(8)4
Avg EPS beat(8)-8.01%
EPS beat(12)8
Avg EPS beat(12)6.82%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.76%
PT rev (3m)-1.38%
EPS NQ rev (1m)6.56%
EPS NQ rev (3m)3.54%
EPS NY rev (1m)-0.4%
EPS NY rev (3m)3.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.13
P/tB 2.31
EV/EBITDA N/A
EPS(TTM)-2.26
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-1.01
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpSN/A
BVpS3.58
TBVpS3.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.59%
ROE -37.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.67%
ROA(5y)-49.46%
ROE(3y)-73.83%
ROE(5y)-61.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset TurnoverN/A
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9
Quick Ratio 9
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y34.3%
EPS Next 2Y16.11%
EPS Next 3Y10.16%
EPS Next 5Y16.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.33%
EBIT Next 3Y-7.98%
EBIT Next 5Y14.14%
FCF growth 1Y-64.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.77%
OCF growth 3YN/A
OCF growth 5YN/A